Not provided
Not provided
Not provided
Not provided
Not provided
Internal decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Winicker Norimed GmbH | INDUSTRY |
Not provided
Not provided
Not provided
The purpose of the current investigation is to provide proof of concept for a future approach to improve UF prediction accuracy. While building on the ideas of the past, the concept is augmented by leveraging additional diagnostic technologies and digital data analytics methodologies.
The primary objective of this study is:
- UFV determined per defined dwells with variable dwell duration, dialysis fluid glucose composition and inflow volumes
The secondary objectives of this study are:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Peritoneal dialysis (PD) | Other | During the clinical phase, patients are treated continuously with the PD cycler sleep•safe harmony. The total duration of the clinical for the individual patient comprises a maximum of 17 weeks starting from V0 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PD cycler | Device | After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.
|
| Measure | Description | Time Frame |
|---|---|---|
| Ultrafiltration volume (UFV) | UFV determined per defined dwells with variable dwell duration, dialysis fluid glucose composition and inflow volumes. | every day during the 11 weeks treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Fluid status | Fluid status measured by Body Composition Monitor (BCM) | At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| 24 h batch collection | RRF (24 h urine output) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Isabel Garcia Méndez, Dr. | Hospital Son Espases | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Prospective, multi-centric, interventional
Not provided
Not provided
Not provided
Not provided
|
| At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| 24 h batch collection | RRF (GFR) | At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| 24 h batch collection | RRF (renal creatinine clearance) | At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| 24 h batch collection | RRF (renal urea clearance) | At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| 24 h batch collection | Peritoneal urea clearance | At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| 24 h batch collection | Peritoneal creatinine clearance | At study start, and then after 3 weeks, 4 weeks and 5 weeks. |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |